Research progress on anticoagulation strategies for prevention and treatment of venous thromboembolism in patients with obesity
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 32, Issue 11, Pages: 933-937(2023)
- 作者机构：
重庆医科大学附属第二医院血管外科，重庆 400010
- 作者简介：
- 基金信息：
DOI：10.11659/jjssx.02E023078
CLC： R543.6Published：25 November 2023，
Received：15 February 2023，
扫 描 看 全 文
刘俊杰,唐博.肥胖患者预防及治疗静脉血栓栓塞症抗凝策略的研究进展[J].局解手术学杂志,2023,32(11):933-937.
LIU Jun-jie,TANG Bo.Research progress on anticoagulation strategies for prevention and treatment of venous thromboembolism in patients with obesity[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(11):933-937.
刘俊杰,唐博.肥胖患者预防及治疗静脉血栓栓塞症抗凝策略的研究进展[J].局解手术学杂志,2023,32(11):933-937. DOI： 10.11659/jjssx.02E023078.
LIU Jun-jie,TANG Bo.Research progress on anticoagulation strategies for prevention and treatment of venous thromboembolism in patients with obesity[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(11):933-937. DOI： 10.11659/jjssx.02E023078.
摘要
肥胖（BMI≥30 kg/m²）已被证实为静脉血栓栓塞症(VTE)的独立危险因素，且肥胖程度和VTE发生风险呈显著正相关。已有研究表明，肥胖可能影响VTE患者的抗凝策略，而抗凝是VTE预防及治疗的关键，但固定剂量的抗凝策略对肥胖患者并不都合理。随着我国肥胖发病率的逐年上升，肥胖患者预防或治疗VTE的抗凝策略需要重点关注。因此，本文依据现有最新的循证医学证据，就肥胖这类特殊人群如何预防及治疗VTE的进展作一综述，以期为临床合理用药提供更多参考依据。
Abstract
Obesity （with BMI≥30 kg/m
2
） has been proven to be an independent risk factor for venous thromboembolism （VTE），and the degree of obesity is significantly positively correlated with the risk of VTE. Studies have shown that obesity may affect the anticoagulation strategy of VTE patients.Anticoagulation is the key to the prevention and treatment of VTE， but the fixed-dose anticoagulation strategy is not always reasonable for obese patients. With the increasing incidence of obesity in China， the anticoagulation strategies for the prevention or treatment of VTE in obese patients need to be focused on. Therefore， based on the latest evidence-based medical evidence， this article reviews the development of anticoagulation strategies on how to prevent and treat VTE in obese patients， in order to provide more references for the rational use of drugs in clinical practice.
关键词
静脉血栓栓塞症肥胖抗凝低分子肝素新型直接口服抗凝药
Keywords
venous thromboembolismobesityanticoagulationlow molecular weight heparindirect oral anticoagulants
references
中华医学会呼吸病学分会肺栓塞与肺血管病学组，中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会，全国肺栓塞与肺血管病防治协作组.肺血栓栓塞症诊治与预防指南［J］.中华医学杂志，2018，98 （14）：1060-1087.doi：10.3760/cma.j.issn.0376-2491.2018.14.007http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2018.14.007.
Kubitza D，Becka M，Zuehlsdorf M，et al.Body weight has limited influence on the safety，tolerability，pharmacokinetics，or pharmacodynamics of rivaroxaban （BAY 59-7939） in healthy subjects［J］.J Clinl Pharmacol，2007，47（2）：218-226.doi：10.1177/0091270006296058http://dx.doi.org/10.1177/0091270006296058.
Kakkos SK，Gohel M，Baekgaard N，et al.Editor's choice-European society for vascular surgery （ESVS） 2021 clinical practice guidelines on the management of venous thrombosis［J］.Eur J Vasc Endovasc Surg，2021，61（1）：9-82.doi：10.1016/j.ejvs.2020.09.023http://dx.doi.org/10.1016/j.ejvs.2020.09.023.
Zhang Z，Lei J，Shao X，et al.Trends in hospitalization and in-hospital mortality from VTE，2007 to 2016，in China［J］.Chest，2019，155（2）：342-353.doi：10.1016/j.chest.2018.10.040http://dx.doi.org/10.1016/j.chest.2018.10.040.
Ageno W，Becattini C，Brighton T，et al.Cardiovascular risk factors and venous thromboembolism：a meta-analysis［J］.Circulation，2008，117（1）：93-102.doi：10.1161/CIRCULATIONAHA.107.709204http://dx.doi.org/10.1161/CIRCULATIONAHA.107.709204.
Virani SS，Alonso A，Aparicio HJ，et al.Heart disease and stroke statistics-2021 update：a report from the American heart association［J］.Circulation，2021，143（8）：e254-e743.doi：10.1161/cir.0000000000000950http://dx.doi.org/10.1161/cir.0000000000000950.
Pan XF，Wang L，Pan A.Epidemiology and determinants of obesity in China［J］.Lancet Diabetes Endocrinol，2021，9（6）：373-392.doi：10.1016/S2213-8587（21）00045-0http://dx.doi.org/10.1016/S2213-8587（21）00045-0.
Upreti VV，Wang J，Barrett YC，et al.Effect of extremes of body weight on the pharmacokinetics，pharmacodynamics，safety and tolerability of apixaban in healthy subjects［J］.Br J Clin Pharmacol，2013，76（6）：908-916.doi：10.1111/bcp.12114http://dx.doi.org/10.1111/bcp.12114.
Sanderink GJ，Le Liboux A，Jariwala N，et al.The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers［J］.Clin Pharmacol Ther，2002，72（3）：308-318.doi：10.1067/mcp.2002. 127114http://dx.doi.org/10.1067/mcp.2002.127114.
Martin K，Beyer-Westendorf J，Davidson BL，et al.Use of the direct oral anticoagulants in obese patients：guidance from the SSC of the ISTH［J］.J Thromb Haemost，2016，14（6）：1308-1313.doi：10.1111/jth.13323http://dx.doi.org/10.1111/jth.13323.
Stevens SM，Woller SC，Kreuziger LB，et al.Antithrombotic therapy for VTE disease：second update of the chest guideline and expert panel report［J］.Chest，2021，160（6）：e545-e608.doi：10.1016/j.chest.2021.07.055http://dx.doi.org/10.1016/j.chest.2021.07.055.
Ortel TL，Neumann I，Ageno W，et al.American Society of Hematology 2020 guidelines for management of venous thromboembolism：treatment of deep vein thrombosis and pulmonary embolism［J］.Blood Adv，2020，4（19）：4693-4738.doi：10.1182/bloodadvances. 2020001830http://dx.doi.org/10.1182/bloodadvances.2020001830.
Konstantinides SV，Meyer G，Becattini C，et al.2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society （ERS）［J］.Eur Heart J，2020，41（4）：543-603.doi：10.1093/eurheartj/ehz405http://dx.doi.org/10.1093/eurheartj/ehz405.
Fontaine GV，Vigil E，Wohlt PD，et al.Venous thromboembolism in critically Ⅲ medical patients receiving chemoprophylaxis：a focus on obesity and other risk factors［J］.Clin Appl Thromb Hemost，2016，22（3）：265-273.doi：10.1177/1076029615604048http://dx.doi.org/10.1177/1076029615604048.
Walker CK，Sandmann EA，Horyna TJ，et al.Increased enoxaparin dosing for venous thromboembolism prophylaxis in general trauma patients［J］.Ann Pharmacother，2017，51（4）：323-331.doi：10.1177/1060028016683970http://dx.doi.org/10.1177/1060028016683970.
Imberti D，Baldini E，Pierfranceschi MG，et al.Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery：a prospective，randomised pilot study evaluating two doses of parnaparin （BAFLUX Study）［J］.Obes Surg，2014，24（2）：284-291.doi：10.1007/s11695-013-1105-xhttp://dx.doi.org/10.1007/s11695-013-1105-x.
Kalfarentzos F，Stavropoulou F，Yarmenitis S，et al.Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin （nadroparin） in bariatric surgery：a prospective randomized trial［J］.Obes Surg，2001，11（6）：670-676.doi：10.1381/09608920160558588http://dx.doi.org/10.1381/09608920160558588.
Vavken P，Lunzer A，Grohs JG.A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery［J］.Wien Klin Wochenschr，2009，121（13/14）：454-458.doi：10.1007/s00508-009-1175-xhttp://dx.doi.org/10.1007/s00508-009-1175-x.
Scholten DJ，Hoedema RM，Scholten SE.A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery［J］.Obes Surg，2002，12（1）：19-24.doi：10.1381/096089202321144522http://dx.doi.org/10.1381/096089202321144522.
Miranda S，Le Cam-Duchez V，Benichou J，et al.Adjusted value of thromboprophylaxis in hospitalized obese patients：a comparative study of two regimens of enoxaparin：the ITOHENOX study［J］.Thromb Res，2017，155：1-5.doi：10.1016/j.thromres.2017.04.011http://dx.doi.org/10.1016/j.thromres.2017.04.011.
Steib A，Degirmenci SE，Junke E，et al.Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery：effects on antifactor Xa activity and procoagulant microparticles.A randomized controlled study［J］.Surg Obes Relat Dis，2016，12（3）：613-621.doi：10.1016/j.soard.2015.08.505http://dx.doi.org/10.1016/j.soard.2015.08.505.
Simone EP，Madan AK，Tichansky DS，et al.Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery［J］.Surg Endosc，2008，22（11）：2392-2395.doi：10.1007/s00464-008-9997-6http://dx.doi.org/10.1007/s00464-008-9997-6.
Wang TF，Milligan PE，Wong CA，et al.Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients［J］.Thromb Haemost，2014，111（1）：88-93.doi：10.1160/TH13-01-0042http://dx.doi.org/10.1160/TH13-01-0042.
Hamad GG，Choban PS.Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery：findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin （PROBE） study［J］.Obes Surg，2005，15（10）：1368-1374.doi：10.1381/096089205774859245http://dx.doi.org/10.1381/096089205774859245.
Gibson CM，Hall C，Davis S，et al.Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients［J］.J Thromb Thrombolysis，2021，52（2）：577-583.doi：10.1007/s11239-020-02360-9http://dx.doi.org/10.1007/s11239-020-02360-9.
Gelikas S，Eldar SM，Lahat G.Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy：2 different dosing regimens of enoxaparin［J］.Surg Obes Relat Dis，2017，13（10）：1753-1759.doi：10.1016/j.soard.2017.07.027http://dx.doi.org/10.1016/j.soard.2017.07.027.
Mirza R，Nieuwlaat R，Lopez-Nunez JJ，et al.Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity （RIETE registry）［J］.Blood Adv，2020，4（11）：2460-2467.doi：10.1182/bloodadvances.2019001373http://dx.doi.org/10.1182/bloodadvances.2019001373.
Thompson-Moore NR，Wanat MA，Putney DR，et al.Evaluation and pharmacokinetics of treatment dose enoxaparin in hospitalized patients with morbid obesity［J］.Clin Appl Thromb Hemost，2015，21（6）：513-520.doi：10.1177/1076029614568713http://dx.doi.org/10.1177/1076029614568713.
Curry MA，Lafollette JA，Alexander BR，et al.Evaluation of treatment-dose enoxaparin in acutely Ⅲ morbidly obese patients at an academic medical center：a randomized clinical trial［J］.Ann Pharmacother，2019，53（6）：567-573.doi：10.1177/1060028018821149http://dx.doi.org/10.1177/1060028018821149.
Van Oosterom N，Winckel K，Barras M.Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity［J］.J Thromb Thrombolysis，2019，48（3）：387-393.doi：10.1007/s11239-019-01847-4http://dx.doi.org/10.1007/s11239-019-01847-4.
Maclachlan KH，Stevens HP，Tran HA，et al.Weight-based enoxaparin for venous thromboembolism in obesity gives similar anti-Xa levels to patients<100 kg，with no increase in major bleeding［J］.Semin Thromb Hemost，2019，45（1）：94-99.doi：10.1055/s-0038-1677019http://dx.doi.org/10.1055/s-0038-1677019.
Smith J，Canton EM.Weight-based administration of dalteparin in obese patients［J］.Am J Health Syst Pharm，2003，60（7）：683-687.doi：10.1093/ajhp/60.7.683http://dx.doi.org/10.1093/ajhp/60.7.683.
Liu J，Qiao X，Wu M，et al.Strategies involving low-molecular-weight heparin for the treatment and prevention of venous thromboembolism in patients with obesity：a systematic review and meta-analysis［J］.Front Endocrinol （Lausanne），2023，14：1084511.doi：10.3389/fendo.2023.1084511http://dx.doi.org/10.3389/fendo.2023.1084511.
Eriksson BI，Dahl OE，Feuring M，et al.Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery：a pooled analysis［J］.Thromb Res，2012，130（5）：818-820.doi：10.1016/j.thromres.2012.07.004http://dx.doi.org/10.1016/j.thromres.2012.07.004.
Pineo GF，Gallus AS，Raskob GE，et al.Apixaban after hip or knee arthroplasty versus enoxaparin：efficacy and safety in key clinical subgroups［J］.J Thromb Haemos，2013，11（3）：444-451.doi：10.1111/jth.12109http://dx.doi.org/10.1111/jth.12109.
Krauss ES，Cronin M，Dengler N，et al.The effect of BMI and gender on bleeding events when rivaroxaban is administered for thromboprophylaxis following total hip and total knee arthroplasty［J］.Semin Thromb Hemost，2019，45（2）：180-186.doi：10.1055/s-0038-1676319http://dx.doi.org/10.1055/s-0038-1676319.
Choi Y，Kushnir MB，Henny H.Apixaban is safe and effective in morbidly obese patients：a retrospective analysis of 390 patients with BMI ≥40［J］.Blood，2017，130（Suppl 1）：1105.doi：10.1182/blood.V130.Suppl_1.1105.1105http://dx.doi.org/10.1182/blood.V130.Suppl_1.1105.1105.
Kalani C，Awudi E，Alexander T，et al.Evaluation of the efficacy of direct oral anticoagulants （DOACS） in comparison to warfarin in morbidly obese patients［J］.Hosp Pract（1995），2019，47（4）：181-185.doi：10.1080/21548331.2019.1674586http://dx.doi.org/10.1080/21548331.2019.1674586.
Kido K，Ngorsuraches S.Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation［J］.Anna Pharmacother，2019，53（2）：165-170.doi：10.1177/10600280187966http://dx.doi.org/10.1177/10600280187966.
Kushnir M，Choi Y，Eisenberg R，et al.Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity：a single-centre，retrospective analysis of chart data［J］.Lancet Haematol，2019，6（7）：e359-e365.doi：10.1016/s2352-3026（19）30086-9http://dx.doi.org/10.1016/s2352-3026（19）30086-9.
Mai V，Marceau-Ferron E，Bertoletti L，et al.Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity：a systematic review with meta-analysis［J］.Pharmacol Res，2021，163：105317.doi：10.1016/j.phrs.2020.105317http://dx.doi.org/10.1016/j.phrs.2020.105317.
0
Views
2
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
